Keyphrases
Non-small Cell Lung Cancer (NSCLC)
90%
Lung Cancer
49%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
46%
Whole Genome
33%
Tumor
32%
Pan-cancer Analysis
31%
Phase II Study
23%
Overall Survival
20%
Carboplatin
20%
In Cancer
18%
Chemotherapy
18%
Cancer Genome Atlas
18%
Cancer Types
17%
Pemetrexed
17%
Human Cancer
16%
Phase II Trial
16%
Targeted Therapy
16%
Small Cell Lung Cancer
16%
Lung Adenocarcinoma
13%
Oncology
12%
Docetaxel
12%
Cisplatin
11%
Phase I Study
10%
Bevacizumab
10%
Non-squamous Non-small Cell Lung Cancer
10%
Confidence Interval
10%
Progression-free Survival
10%
Clinical Trials
9%
Early-stage Lung Cancer
9%
Genetic Modification
9%
Previously Treated
9%
Hazard Ratio
8%
Erlotinib
8%
Brain Metastases
8%
Stable Disease
8%
Adjuvant Chemotherapy
8%
Platinum-based Chemotherapy
8%
Tumor Subtype
8%
Epidermal Growth Factor Receptor
8%
Molecular Characterization
8%
Paclitaxel
7%
Radiation Therapy
7%
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
7%
Lung Squamous Cell Carcinoma
7%
Stage III Non-small Cell Lung Cancer
7%
Patient-derived Xenograft
7%
NCCN Guidelines
7%
Solid Tumors
7%
Clinical Practice Guidelines
7%
Gefitinib
7%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Lung Cancer
46%
Chemotherapy
36%
Diseases
26%
Malignant Neoplasm
25%
Overall Survival
24%
Neoplasm
22%
Carboplatin
20%
Small Cell Lung Cancer
18%
Paclitaxel
17%
Pemetrexed
14%
Progression Free Survival
13%
Clinical Trial
12%
Phase II Trials
12%
Docetaxel
11%
Epidermal Growth Factor Receptor
11%
Cisplatin
10%
Solid Malignant Neoplasm
10%
Adverse Event
9%
Bevacizumab
9%
Erlotinib
7%
Chemoradiation Therapy
7%
Brain Metastasis
6%
Gefitinib
6%
Biological Marker
6%
Irinotecan
6%
Etoposide
6%
Maximum Tolerated Dose
6%
Lung Adenocarcinoma
5%
Cetuximab
5%
Esophagus Cancer
5%
Adenocarcinoma
5%
Survival Rate
5%
Medicine and Dentistry
Non Small Cell Lung Cancer
77%
Lung Cancer
50%
Malignant Neoplasm
45%
Neoplasm
29%
Diseases
22%
Overall Survival
18%
Small Cell Lung Cancer
18%
Targeted Therapy
13%
Pemetrexed
13%
Oncology
12%
Cancer
12%
Carboplatin
9%
Radiation Therapy
9%
Lung Adenocarcinoma
9%
The Cancer Genome Atlas
8%
Paclitaxel
8%
Arm
7%
Recurrent Disease
7%
Bevacizumab
7%
Metastatic Carcinoma
7%
Cancer Types
7%
Progression Free Survival
7%
Biological Marker
7%
Positron Emission Tomography
6%
Epidermal Growth Factor Receptor
6%
Clinical Oncology
6%
Adjuvant Chemotherapy
6%
Squamous Cell Lung Carcinoma
6%
Surgery
6%
Clinical Trial
6%
Immunotherapy
6%
Chemoradiotherapy
5%
Lung
5%
Somatics
5%
Brain Metastasis
5%
Cisplatin
5%
Next Generation Sequencing
5%